TY - JOUR
T1 - Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer
AU - Aktas, Bahriye
AU - Fehm, Tanja N
AU - Welslau, Manfred
AU - Müller, Volkmar
AU - Lüftner, Diana
AU - Schütz, Florian
AU - Fasching, Peter A
AU - Janni, Wolfgang
AU - Thomssen, Christoph
AU - Witzel, Isabell
AU - Belleville, Erik
AU - Untch, Michael
AU - Thill, Marc
AU - Tesch, Hans
AU - Ditsch, Nina
AU - Lux, Michael P
AU - Banys-Paluchowski, Maggie
AU - Kolberg-Liedtke, Cornelia
AU - Hartkopf, Andreas D
AU - Wöckel, Achim
AU - Kolberg, Hans-Christian
AU - Stickeler, Elmar
AU - Harbeck, Nadia
AU - Schneeweiss, Andreas
N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).
PY - 2022/9
Y1 - 2022/9
N2 - For the treatment of patients with advanced HER2-negative hormone receptor-positive breast cancer, several substances have been introduced into practice in recent years. In addition, other drugs are under development. A number of studies have been published over the past year which have shown either an advantage for progression-free survival or for overall survival. This review summarizes the latest results, which have been published at current congresses or in specialist journals, and classifies them in the clinical treatment context. In particular, the importance of therapy with CDK4/6 inhibitors - trastuzumab deruxtecan, sacituzumab govitecan and capivasertib - is discussed. For trastuzumab deruxtecan, an overall survival benefit in HER2-negative breast cancer with low HER2 expression (HER2-low expression) was reported in the Destiny-Breast-04 study. Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. The lack of overall survival benefit for palbociclib in the first line of therapy raises the question of clinical classification.
AB - For the treatment of patients with advanced HER2-negative hormone receptor-positive breast cancer, several substances have been introduced into practice in recent years. In addition, other drugs are under development. A number of studies have been published over the past year which have shown either an advantage for progression-free survival or for overall survival. This review summarizes the latest results, which have been published at current congresses or in specialist journals, and classifies them in the clinical treatment context. In particular, the importance of therapy with CDK4/6 inhibitors - trastuzumab deruxtecan, sacituzumab govitecan and capivasertib - is discussed. For trastuzumab deruxtecan, an overall survival benefit in HER2-negative breast cancer with low HER2 expression (HER2-low expression) was reported in the Destiny-Breast-04 study. Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. The lack of overall survival benefit for palbociclib in the first line of therapy raises the question of clinical classification.
U2 - 10.1055/a-1912-7362
DO - 10.1055/a-1912-7362
M3 - Journal articles
C2 - 36110891
SN - 0016-5751
VL - 82
SP - 922
EP - 931
JO - Geburtshilfe und Frauenheilkunde
JF - Geburtshilfe und Frauenheilkunde
IS - 9
ER -
